Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 241 of 6351
-
Can a cancer drug help flush out hidden HIV?
Disease control Recruiting nowThe purpose of this study is to evaluate whether a single dose of Nivolumab in people living with HIV can reduce the latent reservoir. The latent HIV reservoir is a group of immune system cells in the body that are infected with HIV but are not actively producing new virus. This …
Phase 1/2 • Sponsor: University of Melbourne • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Virtual visits after heart failure hospitalization: a lifeline or a gamble?
Disease control Recruiting nowThe clinic visits (intervention) will continue for 90 days, which represents the follow-up period for the primary medication and health status outcomes. The co-primary clinical outcomes will be obtained at 180 days.
Sponsor: Population Health Research Institute • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a drug combo shrink bile duct tumors before surgery?
Disease control Recruiting nowThis phase II trial studies how well gemcitabine, cisplatin, nab-paclitaxel and durvalumab work before surgery in treating participants with Biliary Tract Cancer. The international multicenter phase III clinical study TOPAZ-1 has confirmed that durvalumab combined with gemcitabin…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study is intended to evaluate the ability of SENS-401 to prevent the ototoxicity induced by cisplatin in subjects with a neoplastic disease. It is a multicenter, randomized, controlled, two-arm, open-label efficacy and safety study in adults with neoplastic disease requiring…
Phase 2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New bladder cancer drug could help patients avoid bladder removal
Disease control OngoingThis is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to…
Phase 3 • Sponsor: Fidia Farmaceutici s.p.a. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New lung cancer cocktail aims to outperform current standard in phase 3 trial
Disease control OngoingThis is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemothe…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Triple therapy shows promise for advanced liver cancer
Disease control CompletedThe purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage hepatocellular carcinoma (HCC).
Sponsor: Zhongda Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can a single pill tackle both fatty liver and diabetes?
Disease control CompletedA phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have type 2 diabetes mellitus or pre-diabetes.
Phase 2 • Sponsor: HighTide Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug could save limbs without surgery
Disease control Recruiting nowObjective: to evaluate the efficacy and safety of intra-arterial intrathrombus administration of the recombinant non-immunogenic staphylokinase (Fortelyzin®) in patients with acute limb ischemia (ALI) vs surgery.
Phase 3 • Sponsor: Supergene, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a common gout drug save hearts? colchicine trial targets valve disease
Disease control OngoingAortic stenosis (AS) is the most common valvular heart disease in the developed world. Once symptomatic, untreated patients have a poor prognosis with five-year survival rate of 25%. Once at an advanced stage, AS will lead to the development of left ventricle hypertrophy, and eve…
Phase 3 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can Pre-Surgery drug cocktail stop liver cancer from coming back?
Disease control OngoingTo evaluate the safety and efficacy of HAIC or Lenvatinib combined with Sintilimab as a neoadjuvant therapy for high recurrence risk resectable stage IB solitary hepatocellular carcinoma
Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Could a drug combo free kidney transplant patients from lifelong pills?
Disease control Stopped earlyThe purpose of this study is to evaluate if TCD601 can induce allogeneic tolerance in living donor renal transplant recipients
Phase 2 • Sponsor: ITB-Med LLC • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat head and neck cancers
Disease control CompletedThis study is the first clinical study in PD-1 resistant patients with head and neck squamous cell carcinoma with drugs targeting EGFR signaling pathway combined with CDK4/6 inhibitors, which explores the new combination therapies urgently needed in clinical practice and lays a f…
Phase 2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo therapy aims to stall liver cancer progression
Disease control Recruiting nowThe purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy con…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Therapy may let kids with OCD ditch meds for good
Disease control Recruiting nowThe purpose of this study is to examine whether youth with OCD who benefit from CBT augmentation to SRI can discontinue their medication without relapse over 24 weeks.
Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can higher doses of TB drugs cut treatment time?
Disease control PausedTuberculosis (TB) treatment is long and complex with the risk of poor treatment adherence and treatment failure. Several attempts to shorten treatment of drug-susceptible TB have been unsuccessful. However, recent data support a shortened regimen for mild and moderate pulmonary T…
Phase 2 • Sponsor: University Hospital, Linkoeping • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Can a 5-Day pill tame RSV in the most vulnerable?
Disease control CompletedThis was a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult subjects with confirmed RSV infection who were at high risk for complications after RSV infection.
Phase 2 • Sponsor: Enanta Pharmaceuticals, Inc • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Fat mapping MRI could spot breast cancer years earlier
Diagnosis CompletedBreast cancer is a major and growing health challenge, and the leading cause of cancer in women. As population obesity rates increase, the number of new breast cancer diagnosis continues to rise. Despite treatment advances, breast cancer remains an important cause of premature mo…
Sponsor: University of Aberdeen • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
3D imaging could help surgeons remove all breast cancer in one go
Disease control CompletedThis clinical trial assesses if the use of a three-dimensional imaging device called the Clarix Imaging Volumetric Specimen Imager (VSI) can help guide and assist surgeons in identifying and removing all positive margins while in the operating room (intraoperative imaging) for pa…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
A tiny dose of an old drug might stop Post-Surgery brain fog in seniors
Prevention Stopped earlyThe aim of this multicenter, prospective, randomized, double-blind and large sample study is to explore the preventive effect of low-dose droperidol on POD in elderly patients after non-cardiac surgery, providing new approach for reducing the incidence of POD and improving the pr…
Sponsor: RenJi Hospital • Aim: Prevention
Last updated Aug 14, 2026 00:00 UTC